GNF-5 is primarily utilized in research settings as a potent and selective inhibitor of the Bcr-Abl tyrosine kinase, particularly targeting the T315I mutant form. Its application is significant in the study of chronic myeloid leukemia (CML) and other cancers driven by Bcr-Abl mutations. Researchers employ GNF-5 to investigate resistance mechanisms in cancer therapies, especially in cases where patients develop resistance to first-line treatments like imatinib. Additionally, it serves as a valuable tool in preclinical studies to evaluate the efficacy of novel therapeutic strategies aimed at overcoming drug resistance in cancer treatment.